• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Calidi Biotherapeutics and Gorilla Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    10/18/24 8:45:00 AM ET
    $BOXL
    $CLDI
    $GRRR
    Other Consumer Services
    Real Estate
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BOXL alert in real time by email

    ORLANDO, FL / ACCESSWIRE / October 18, 2024 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE:CLDI) and Gorilla Technology Group Inc. (NASDAQ:GRRR) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 19, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

    Access the interviews in their entirety at:

    • Calidi: https://www.redchip.com/assets/access/cldi_access

    • Gorilla Technology: https://www.redchip.com/assets/access/grrr_access

    In an exclusive interview, Stephen Thesing, Chief Business Officer of Calidi, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. Calidi is at the forefront of oncolytic virotherapy (OV), a promising multi-billion-dollar area in cancer treatment. Calidi is pioneering the development of both systemic and localized OVs, leveraging engineered viruses to target and destroy cancer cells while arming the immune system for a comprehensive attack on tumors. Calidi's cell-based technologies uniquely protect OVs from immune system elimination, ensuring higher efficacy and opening the tumor microenvironment to treatment. This approach has shown promising efficacy in initial studies, while their breakthrough IV-based technology and direct tumor administration methods differentiate them within the multi-billion-dollar oncology field.

    Jay Chandan, Chairman and CEO of Gorilla Technology, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. With over 22 years of operational excellence and a portfolio of 29 granted patents globally, Gorilla has established itself as a leader in delivering transformative solutions that drive large-scale digital transformation. The company's advanced technologies, including edge AI, big data analytics, IoT security, and virtualization infrastructure, empower clients across critical sectors such as government, public safety, manufacturing, and energy management to create smarter, safer and more efficient environments. Gorilla's strong financial foundation, innovative technology, and strategic market expansion provide a solid basis for long-term value creation as it continues to lead in the global digital transformation landscape. Gorilla has buy ratings and a mean price target of $29.50 from three analysts.

    About Calidi Biotherapeutics

    Calidi Biotherapeutics (NYSE:CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi's novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi's clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi's preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com.

    About Gorilla Technology Group Inc.

    Headquartered in London U.K., Gorilla is a global solution provider in Security Intelligence, Network Intelligence, Business Intelligence and IoT technology. We provide a wide range of solutions, including, Smart City, Network, Video, Security Convergence and IoT, across select verticals of Government & Public Services, Manufacturing, Telecom, Retail, Transportation & Logistics, Healthcare and Education, by using AI and Deep Learning Technologies.

    Our expertise lies in revolutionizing urban operations, bolstering security and enhancing resilience. We deliver pioneering products that harness the power of AI in intelligent video surveillance, facial recognition, license plate recognition, edge computing, post-event analytics and advanced cybersecurity technologies. By integrating these AI-driven technologies, we empower Smart Cities to enhance efficiency, safety and cybersecurity measures, ultimately improving the quality of life for residents.

    For more information, please visit our website: https://www.gorilla-technology.com/

    About RedChip Companies

    RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

    To learn more about RedChip's products and services, please visit:

    https://www.redchip.com/corporate/investor_relations

    "Discovering Tomorrow's Blue Chips Today"™

    Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/

    Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies

    Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/

    Follow RedChip on Twitter: https://twitter.com/RedChip

    Follow RedChip on YouTube: https://www.youtube.com/@redchip

    Follow RedChip on Rumble: https://rumble.com/c/c-3068340

    Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

    Contact:

    Dave Gentry
    RedChip Companies Inc.
    1-407-644-4256
    [email protected]

    --END--

    SOURCE: RedChip



    View the original press release on accesswire.com

    Get the next $BOXL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • When will the interviews with Calidi Biotherapeutics and Gorilla Technology air?

      The interviews with Calidi Biotherapeutics and Gorilla Technology will air on Bloomberg TV on October 19, 2024, at 7 p.m. Eastern Time.

    • What area of cancer treatment does Calidi Biotherapeutics focus on?

      Calidi Biotherapeutics specializes in oncolytic virotherapy, leveraging engineered viruses to target and destroy cancer cells, while also enhancing immune response to fight tumors.

    • What technologies does Gorilla Technology Group specialize in?

      Gorilla Technology Group is a leader in digital solutions, particularly in edge AI, big data analytics, and IoT security, aimed at transforming operations in government, public safety, and manufacturing.

    • How does Calidi Biotherapeutics' technology differentiate itself in the oncology field?

      Calidi's unique approach involves using stem cell-based platforms that can carry oncolytic viruses, offering a safer and more efficient way to treat cancer.

    • What is the current analyst rating and price target for Gorilla Technology Group?

      Analysts have rated Gorilla Technology with buy ratings and have set a mean price target of $29.50.

    Recent Analyst Ratings for
    $BOXL
    $CLDI
    $GRRR

    CompanyDatePrice TargetRatingAnalyst
    Boxlight Corporation
    $BOXL
    11/14/2024Buy → Neutral
    Alliance Global Partners
    Calidi Biotherapeutics Inc.
    $CLDI
    11/22/2023$11.00Buy
    H.C. Wainwright
    Calidi Biotherapeutics Inc.
    $CLDI
    10/9/2023$9.00Outperform
    Robert W. Baird
    Gorilla Technology Group Inc.
    $GRRR
    7/26/2023$4.80Overweight
    Cantor Fitzgerald
    Boxlight Corporation
    $BOXL
    12/13/2021$4.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BOXL
    $CLDI
    $GRRR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Boxlight downgraded by Alliance Global Partners

      Alliance Global Partners downgraded Boxlight from Buy to Neutral

      11/14/24 7:24:06 AM ET
      $BOXL
      Other Consumer Services
      Real Estate
    • H.C. Wainwright initiated coverage on Calidi Biotherapeutics with a new price target

      H.C. Wainwright initiated coverage of Calidi Biotherapeutics with a rating of Buy and set a new price target of $11.00

      11/22/23 7:15:52 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Robert W. Baird initiated coverage on Calidi Biotherapeutics with a new price target

      Robert W. Baird initiated coverage of Calidi Biotherapeutics with a rating of Outperform and set a new price target of $9.00

      10/9/23 7:23:07 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BOXL
    $CLDI
    $GRRR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Boxlight and Raptor Technologies® Integrate Silent, Location-Based Alerts with Campus-Wide Communication

      Raptor Alert activates Boxlight's ATTENTION! system to deliver immediate visual and audio messages across school campuses based on location-specific alerts. Boxlight Corporation (NASDAQ:BOXL)—recognized as one of the top ed-tech companies in the world for innovative solutions that enhance communication and collaboration in educational institutions and businesses—announces a strategic partnership with Raptor Technologies®, a premier provider of school safety software. This integration connects Raptor® Alert™, a silent panic alert and emergency notification platform, with Boxlight's ATTENTION! communication ecosystem, equipping schools to deliver timely, coordinated emergency responses with

      5/6/25 9:01:00 AM ET
      $BOXL
      Other Consumer Services
      Real Estate
    • Gorilla Technology Releases Full Year Audited Financials for 2024

      London, United Kingdom--(Newsfile Corp. - April 30, 2025) - Gorilla Technology Group Inc. (NASDAQ:GRRR) ("Gorilla" or the "Company"), a global solution provider in Security Intelligence, Network Intelligence, Business Intelligence and IoT technology, today announced that the filing of its full-year audited financials for the year ended 31 December 2024 on Form 20-F with the U.S. Securities and Exchange Commission will be made today after market close.Jay Chandan, Chairman and CEO, commented: "2024 was the year we moved from transformation to acceleration. We have cemented our position in the AI ecosystem, and we are building the digital infrastructure that will power governments and enterpri

      4/30/25 9:00:00 AM ET
      $GRRR
      Computer Software: Prepackaged Software
      Technology
    • Calidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy Platform at AACR Annual Meeting

      SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the selection of IL15 superagonist (Il15-IL15Ra) as the first payload to be delivered into tumors using its systemic antitumor virotherapy platform, RTNova. New preclinical data were presented at the American Association for Cancer Research (AACR) Annual Meeting on April 27, 2025, in Chicago, IL. The first candidate developed using RTNova is a vaccinia virus (virotherapy) that is engineered to be tumor selective and produced in an enveloped form that allows the virus to surv

      4/28/25 8:00:00 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BOXL
    $CLDI
    $GRRR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Gorilla Technology Group Inc.

      SC 13G/A - Gorilla Technology Group Inc. (0001903145) (Subject)

      12/6/24 9:25:12 PM ET
      $GRRR
      Computer Software: Prepackaged Software
      Technology
    • Amendment: SEC Form SC 13G/A filed by Calidi Biotherapeutics Inc.

      SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

      11/14/24 2:05:25 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Gorilla Technology Group Inc.

      SC 13G/A - Gorilla Technology Group Inc. (0001903145) (Subject)

      9/17/24 6:53:48 PM ET
      $GRRR
      Computer Software: Prepackaged Software
      Technology

    $BOXL
    $CLDI
    $GRRR
    Financials

    Live finance-specific insights

    See more
    • Gorilla Technology Releases Full Year Audited Financials for 2024

      London, United Kingdom--(Newsfile Corp. - April 30, 2025) - Gorilla Technology Group Inc. (NASDAQ:GRRR) ("Gorilla" or the "Company"), a global solution provider in Security Intelligence, Network Intelligence, Business Intelligence and IoT technology, today announced that the filing of its full-year audited financials for the year ended 31 December 2024 on Form 20-F with the U.S. Securities and Exchange Commission will be made today after market close.Jay Chandan, Chairman and CEO, commented: "2024 was the year we moved from transformation to acceleration. We have cemented our position in the AI ecosystem, and we are building the digital infrastructure that will power governments and enterpri

      4/30/25 9:00:00 AM ET
      $GRRR
      Computer Software: Prepackaged Software
      Technology
    • Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights

      Announced demonstrated ability to deliver transient gene therapy (payload) to tumors using systemic antitumor virotherapy platform Filed IND in March 2025 for CLD-201 company sponsored Phase 1 trial to treat multiple solid tumorsCommencement of recruitment for Phase 1 trial in patients with newly diagnosed high-grade glioma at Northwestern University hospital14 patients enrolled in Phase 1 trial conducted by City of Hope to treat recurrent high-grade glioma SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today reported its fourth quarter and fu

      3/31/25 4:10:00 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Boxlight Reports Fourth Quarter and Full Year 2024 Financial Results

      Boxlight Corporation (NASDAQ:BOXL) ("Boxlight" or the "Company"), a leading provider of interactive technology solutions, today announced the Company's financial results for the fourth quarter and full year ended December 31, 2024. Financial and Operational Highlights: Revenue was $24.0 million for the quarter, a decrease of 38.2% from the prior year quarter Gross profit margin in Q4'24 decreased by 110 basis points to 30.6% from the prior year quarter Net loss for the quarter was $16.7 million, inclusive of accelerated amortization of $12.3 million, compared to net loss of $17.7 million in the prior year quarter, inclusive of non-recurring impairment charges of $12.0 million. Net

      3/28/25 4:05:00 PM ET
      $BOXL
      Other Consumer Services
      Real Estate

    $BOXL
    $CLDI
    $GRRR
    SEC Filings

    See more
    • Calidi Biotherapeutics Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

      5/2/25 4:30:13 PM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Gorilla Technology Group Inc.

      SCHEDULE 13G/A - Gorilla Technology Group Inc. (0001903145) (Subject)

      5/2/25 4:10:10 PM ET
      $GRRR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 20-F filed by Gorilla Technology Group Inc.

      20-F - Gorilla Technology Group Inc. (0001903145) (Filer)

      4/30/25 4:57:23 PM ET
      $GRRR
      Computer Software: Prepackaged Software
      Technology

    $BOXL
    $CLDI
    $GRRR
    Leadership Updates

    Live Leadership Updates

    See more
    • Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

      SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that in connection with the appointment of Eric Poma, Ph.D. as Chief Executive Officer , the Company's Compensation Committee and the Board of Directors has approved the grant of an inducement non-qualified stock option for Dr. Poma for the purchase of 726,412 shares with an exercise price of $0.469, which was the closing price of the Company's common stock on April 22, 2025, the date of grant (the "Stock Options"). The Stock Options vest over four years with 25% of the Stoc

      4/25/25 8:00:00 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

      SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the succession of its Chief Executive Officer ("CEO"), Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi ("Board"), effective April 22, 2025. Mr. Camaisa will continue to serve as a member of the Board. "We are pleased to welcome Eric as Calidi's new CEO, given his deep experience in life science leadership with a focus on oncology, as Calidi advances its systemic enveloped virotherapy platform to the clinic and prepa

      4/23/25 8:00:00 AM ET
      $CLDI
      $MTEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Gorilla Technology Appoints AI Visionary Satish Venkatesan to Lead Americas Innovation Drive

      Company also reiterates capital allocation priorities through its previously announced share buyback programmeLondon, United Kingdom--(Newsfile Corp. - April 14, 2025) - Gorilla Technology Group Inc. (NASDAQ:GRRR) ("Gorilla" or the "Company"), global solution provider in Security Intelligence, Network Intelligence, Business Intelligence and IoT technology, today announced the appointment of Satish Venkatesan as Chief Solutions Strategist - Americas, effective 14 April 2025.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10783/248385_b66e575ea4d31985_001full.jpgIn this newly created role, Venkatesan will lead Gorilla's solution strategy, ecosyst

      4/14/25 8:00:00 AM ET
      $CTSH
      $GRRR
      EDP Services
      Technology
      Computer Software: Prepackaged Software

    $BOXL
    $CLDI
    $GRRR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Poma Eric E

      4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

      4/25/25 6:05:05 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Poma Eric E

      3 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

      4/25/25 6:01:32 AM ET
      $CLDI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Technology Officer Marklew Shaun sold $1,905 worth of shares (178 units at $10.70), decreasing direct ownership by 3% to 5,178 units (SEC Form 4)

      4 - Boxlight Corp (0001624512) (Issuer)

      4/4/25 5:33:57 PM ET
      $BOXL
      Other Consumer Services
      Real Estate